Repotrectinib: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 April 2024

  • curprev 07:4307:43, 17 April 2024‎ Edzelco talk contribs‎ 32,783 bytes +32,783‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru..."
Retrieved from "https://www.wikidoc.org/index.php/Repotrectinib"